The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation

Drug Metabolism and Disposition

Volumn 33, Issue 6, 2005, Pages 795-802

  Bumpus, Namandjé N ^a   Sridar, Chitra ^a   Kent, Ute M ^a   Hollenberg, Paul F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BENZPHETAMINE; BERGAMOTTIN; COUMARIN DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; EFAVIRENZ; ETHINYLESTRADIOL; FORMALDEHYDE; ISOENZYME; O DEETHYLATE 7 HYDROXY 4 TRIFLUOROMETHYLCOUMARIN; PROPOFOL; THIOTEPA; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; DRUG EFFECT; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME METABOLISM; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MUTATION; OXIDOREDUCTASES, N-DEMETHYLATING; SUBSTRATE SPECIFICITY; VARIATION (GENETICS);

EID: 18844433876     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.105.003749     Document Type: Article

References (34)

1. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golder RN, Martin P, Potter WZ, and Richelson E (1995) Bupropion: a review of its mechanism of anti-depressant activity. J Clin Psychiatry 56:395-401.
2. Chang TK, Weber GF, Crespi CL, and Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res 53:1155-1166.
3. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, and Waxman DJ (1997) Human cytochrome P450 2B6: interindividual hepatic expression, substrate specificity and role in procarcinogen activation. Drug Metab Dispos 25:985-993.
4. Court MH, Duan SX, Hesse LM, Venkatakrishnan K, and Greenblatt DJ (2001) Cytochrome P450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 94:110-119.
5. de Andrade JB, Bispo MS, Rebouças MN, Carvalho MLSM, and Pinheiro HLC (1996) Spectrofluorimetric determination of formaldehyde in liquid samples. Am Lab 8:56-58.
6. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, and Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
7. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, and de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:259-306.
8. Golden RN, De Vane CL, Laizure SC, Rudorfer MV, Sherer MA, and Potter WZ (1988) Bupropion in depression II. The role of metabolites in clinical outcome. Arch Gen Psychiatry 45:145-149.
9. Guengerich FP (1990a) Mechanism-based inactivation of human liver microsomal cytochrome P-450 III A4 by Gestodene. Chem Res Toxicol 3:363-371.
10. Guengerich FP (1990b) Metabolism of 17α-ethynylestradiol in humans. Life Sci 47:1981-1988.
11. Hanna IH, Reed JR, Guengerich FP, and Hollenberg PF (2000) Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression in human liver. Arch Biochem 376:206-216.
12. Hanna IH, Roberts ES, and Hollenberg PF (1998) Molecular basis for the difference in lidocaine binding and the regioselectivity of oxidation by cytochrome P450 2B1 and 2B2. Biochemistry 37:311-318.
13. Harleton E, Webster M, Bumpus NN, Kent UM, Rae JM, and Hollenberg PF (2004) Metabolism of N,N′,N″-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms. J Pharmacol Exp Ther 310:1011-1019.
14. He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, and Hollenberg PF (1998) Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 11:252-259.
15. Hesse LM, Venkatakrishnan K, Court MH, Von Moltke LL, Duan SX, Shader RI, and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183.
16. Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, et al. (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195-1202.
17. Johnston JA, Lineberry CG, Ascher JA, Davidson J, Khayrallah MA, Feighner JP, and Stark P (1991) A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 52:450-456.
18. Kent UM, Mills DE, Rajnarayanan RV, Alworth WL, and Hollenberg PF (2002) Effect of 17-α-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J Pharmacol Exp Ther 300:549-558.
19. Kent UM, Pascual L, Roof RA, Ballou DP, and Hollenberg PF (2004) Mechanistic studies with N-benzyl-1-aminobenzotriazole-inactivated CYP2B1: differential effects on the metabolism of 7-ethoxy-4-(trifluoromethyl)coumarin, testosterone and benzphetamine. Arch Biochem Biophys 423:277-287.
20. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Mürdter TE, Roots I, and Brockmöller J (2003) Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619-626.
21. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
22. Lin H, Kent UM, and Hollenberg PF (2005) The "grapefruit juice effect" is not limited to P450 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther 313:154-164.
23. Maanen MJ, Smeets CJ, and Beijnen JH (2000) Chemistry, pharmacology and pharmacokinetics of N,N′,N″-triethylenethiophosphoramide (tTEPA). Cancer Treat Rev 26:257-268.
24. Oda Y, Hamaoka N, Hiroi T, Imaoka S, Hase I, Tanaka K, Funae Y, Ishizaki T, and Asada A (2001) Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 51:281-285.
25. Preskorn SH (1991) Should bupropion dosage be adjusted based upon therapeutic drug monitoring? Psychopharmacol Bull 27:637-643.
26. Rae JM, Soukhova NV, Flockhart DA, and Desta Z (2002) Triethylenethiophosphamide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 30:525-530.
27. Rendic S and Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-580.
28. Schroeder DH (1983) Metabolism and kinetics of bupropion. J Clin Psychiatry 44:79-81.
29. Scott EE, Spatzenegger M, and Halpert JR (2001) A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility and decreased aggregation while retaining function. Arch Biochem Biophys 395:67-68.
30. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, and Oka S (2004) Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319:1322-1326.
31. Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, and Pelkonen O (2004) Selective inhibition of CYP2B6-catalyzed bupropion hydtoxylation in human liver microsomes in vitro. Drug Metab Dispos 32:626-631.
32. Ward BA, Gorski CJ, Jones DR, Hall SD, Flockhart DA, and Desta Z (2003) The cytochrome P450 2B6 is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as substrate marker of 2B6 catalytic activity. J Pharmacol Exp Ther 306:287-300.
33. Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prince J, Polisner D, Solhkhah R, Comeau S, Monuteaux MC, et al. (2001) A controlled clinical trial of bupropion for attention deficit disorder in adults. Am J Psychiatry 158:282-288.
34. Wooltorton E (2002) Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness. J Can Med Assoc 166:68.